World News

Medicine & Pharmaceuticals

Neurosom announces oversubscribed bridge round financing as company advances towards Seed Round in 1H 2026

January 6, 2026

OR – Neurosom™, the developer of a personalized, at-home neuromodulation therapy to improve deep and REM sleep, key factors in reducing dementia risk, today announced the imminent closing of an oversubscribed bridge round of investment funding for the company. “We are incredibly grateful for this strong show of support for our Sleep WISP ™ technology and the promise it provides for reducing dementia risk, optimizing sleep, and providing brain care as we age,” said Viral Sheth, CEO of Neurosom. The oversubscribed bridge round led by Portland Seed Fund’s Intrepid Oregon Fund with major participation from the Loomis Family Trust, OEN Angel Syndicate and ONAMI reflects strong validation of Neurosom’s technology and clinical trajectory. "The Neurosom team directs decades of neuroscience and product expertise at some of the most pernicious health and longevity issues of our day," said Angela Jackson, managing director of Portland Seed Fund. We are thrilled to have led this investment round and look forward to its growth in the months and years to come." In 2025, other milestones such as the FDA clearance of NEAT, their AI-powered software for the therapy system, and the phase II funding for a clinical trial for Mild Cognitive Impairment, or MCI, funded by the National Institute of Aging, helped drive a stellar year of recognition for Neurosom in the business community. On December 1st, Neurosom won the 2025 Oregon Entrepreneur Network (OEN) Angel Oregon Life & BioScience Fund Investment Award. Sheth comments, “Neurosom is honored to win OEN's Angel Oregon BIO investment. This award serves as a powerful endorsement of our mission to transform deep sleep into a therapeutic gateway for brain health and dementia prevention. The mentorship and network we have been able to build throughout this program have been incredibly valuable. We are deeply grateful to OEN and the Oregon innovation community for their support as we bring Sleep WISP™ closer to the patients and families who need it most.” Path to Seed Round and 2026 Outlook In 2026, the funds raised during the bridge round will be strategically deployed to scale operations and support additional clinical trials for treating MCI. Neurosom has entered active discussions with a small group of specialized neurotechnology investors to anchor a $5M priced seed financing targeted for the first half of 2026. The company will be deepening discussions with a select group of strategic neurotech investors during meetings around the JP Morgan Healthcare Conference. “With multiple data milestones expected in 2026 and growing inbound interest from strategic neurotech VCs, we expect the Seed Round to move quickly,” says Sheth. On the Horizon Key Opinion Leader Sites – the Sleep WISP™ is now in use at Mount Sinai, OHSU, University of Washington, Northwestern University, and Wake Forest University. In 2026, the company will expand its clinical collaborations to additional KOLs and private clinics to broaden the data foundation and accelerate real-world learning. Product Development Neurosom will continue advancing the Sleep WISP™ platform, focusing on improved signal quality and comfort through refinements in hardware and electrodes to support long-term, at-home use with clinical-grade EEG and neuromodulation capability. In parallel, the company is developing an HD EEG based framework for memory and cognitive assessment, integrating longitudinal sleep EEG biomarkers, objective event-related potential (ERP) measures, and emerging biomarkers associated with glymphatic clearance capacity to support earlier detection of cognitive decline and personalized therapy optimization. Qualified investors and strategic partners are encouraged to contact Neurosom through the website to find out more information. About Neurosom™ Neurosom is a medical device company whose mission is to reduce dementia risk and improve brain health by optimizing deep and REM sleep. Founded in 2021, the company developed the innovative, wearable Sleep WISP™ device. The Sleep WISP measures EEG sleep cycles in the home and delivers personalized, painless electrical stimulation using AI-powered, FDA cleared software to extend and enhance deep and REM sleep – the sleep cycles that allow the body to clear the brain of the harmful plaques that cause neurodegenerative diseases. The company is headquartered in Eugene, Oregon and is committed to changing the field of sleep and brain health care. For more information, visit neurosom.net.

1

ALL NEWS

COMMUNICATE. COMMAND. COMMERCE.

Lead the conversation of your brand & win more customers with MarketersMEDIA Solutions.

Explore Now
SUBSCRIBE FOR MORE